B
Bertram Pitt
Researcher at University of Michigan
Publications - 834
Citations - 88351
Bertram Pitt is an academic researcher from University of Michigan. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 107, co-authored 754 publications receiving 78458 citations. Previous affiliations of Bertram Pitt include Rutgers University & Tufts Medical Center.
Papers
More filters
Journal ArticleDOI
New frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review.
TL;DR: In this paper, the authors provide an update on the epidemiology and pathophysiology of obstructive sleep apnea, outlines the mechanistic rationale for medication classes tested as OSA treatment, and discusses the effects of these medications on OSA.
Journal ArticleDOI
Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists.
TL;DR: In patients with HFpEF, one key trial, the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT), found no reduction in risk of cardiovascular mortality but did show a reduced risk for HF-related hospitalization in the spironolactone group as compared to placebo; additionally there were major concerns raised regarding the trial conduct and regional differences in this trial.
Journal ArticleDOI
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
Peter Rossing,Ellen Burgess,Rajiv Agarwal,Stefan D. Anker,Gerasimos Filippatos,Bertram Pitt,Luis M. Ruilope,Pieter Gillard,Richard J MacIsaac,Julio Wainstein,Amer Joseph,Meike Brinker,Lothar Roessig,Charlie Scott,George L. Bakris +14 more
TL;DR: Finerenone reduces kidney and cardiovascular outcome risk in patients with CKD and T2D, and risks appear consistent irrespective of HbA1c levels or insulin use.
Journal ArticleDOI
Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
Javaid Iqbal,Renaud Fay,David Adlam,Iain B. Squire,Yasir Parviz,Julian Gunn,Bertram Pitt,Faiez Zannad +7 more
TL;DR: This EPHESUS substudy examined the effects of eplerenone upon cardiovascular outcomes in PCI‐treated patients.